- Fee assured
- Awaiting verification
- General urology
- Urological oncology
I am a consultant urological surgeon specialising in Uro-oncology and minimally invasive surgery.
I have built a comprehensive practice at Southampton comprising general and diagnostic urology as well as my specialist field of Uro-Oncology. I mainly specialise in prostate cancer diagnostics and treatment.
I am a strong advocate of pre-biopsy multiparametric MRI scans for diagnosis and was Principal Investigator in Southampton for he PROMIS study which established this as the key diagnostic tool for men with high PSA.
I am an expert in MRI guided targeted prostate biopsy (MRI-US fusion) and am one of a handful of surgeons offering both focal ablation and whole gland therapies including robotic prostatectomy, high intensity focused ultrasound and cryotherapy. I am a strong supporter of active surveillance and also work closely with oncologists, supporting them with high dose rate brachytherapy implants. Thus men can be assured that the advice given will tailor their treatment to the risks of the cancer and their own personal circumstances.
During my training I completed fellowships at Imperial College London Hospital NHS Trust and Royal Marsden Hospital NHS Foundation Trust and prior to starting in Southampton, worked as a Consultant at The Royal Marsden Hospital providing bladder, prostate, renal and testicular services.
I am active in cancer research and am leading prostate cancer research trials in Southampton. This includes the INDEX study for focal ablation and studies of the ADx bladder assay a non invasive urine test for bladder cancer.
I have presented my own outcome data at national and international urology conferences including European Robotic Urology Symposium where I was awarded a prize for the best presentation. During my time at The Royal Marsden I also performed the first UK series of robotic retroperitoneal lymph node dissections for post chemotherapy testicular cancer patients.
I am enthusiastic about teaching men about the confusing, often conflicting, ideas about prostate cancer testing and treatment. I seek to carefully risk assess men and try to avoid over diagnosis and over treatment.
I am experienced in general urology and enjoy helping patients with common urological problems.
Areas of interest
Prostate cancer; Bladder cancer; Kidney cancer; Testicular cancer; Laparoscopy; Robotic surgery; HIFU; Cryotherapy; Prostatitis; Recurrent urine infections; Painful bladder syndrome; Circumcision:Foreskin preserving surgery for phimosis, laparoscopcic varicocoele surgery,
- Kirsten Dittrich
- Spire Southampton Hospital Chalybeate Close SOUTHAMPTON SO16 6UY
- 023 8076 4391
- 023 8091 4413
- Video and telephone consultations
Anaesthetists worked with
- Dr Samar Al-Rawi Not Fee Assured
- Dr Julian Nixon Not Fee Assured
- Dr Benjamin Skinner Not Fee Assured
- Dr Irina Grecu Fee Assured
- Dr Roy Kukreja Fee Assured
Current NHS consultant posts held
University Hospital Southampton
Urinary diagnosis of prostate and bladder cancer (Urosens - Mcm5)
PART - Randomised trial of surgery Vs HIFU
INDEX - cohort study of focal HIFU
TRUE Nth - surgical outcomes study
Mcm5 diagnostic study for bladder cancer
CALIBER - intravesical chemotherapy vs surgery for recurrent TCC bladder
FORECAST - salvage HIFU for recurrent prostate cancer
Family, cooking, travelling, music, F1, chess
Bladder cancer diagnosis and identification of clinically significant disease by combined urinary detection of Mcm5 and nuclear matrix protein 22.
Kelly JD, Dudderidge TJ, et al
PLoS One. 2012;7(7):e40305.
Evolution of care pathway for laparoscopic radical prostatectomy.
Dudderidge TJ, et al
J Endourol. 2012 Jun;26(6):660-5.
Diagnosis of prostate cancer by detection of minichromosome maintenance 5 protein in urine sediments.
Dudderidge TJ, et al
Br J Cancer. 2010 Aug 24;103(5):701-7.
High-intensity focused ultrasound for localized prostate cancer: initial experience with a 2-year follow-up.
Dudderidge T, Ahmed H, Emberton M.
BJU Int. 2009 Oct;104(8):1170-1;
High-intensity-focused ultrasound in the treatment of primary prostate cancer: the first UK series.
Ahmed HU, Zacharakis E, Dudderidge T, Armitage JN, Scott R, Calleary J, Illing R, Kirkham A, Freeman A, Ogden C, Allen C, Emberton M.
Br J Cancer. 2009 Jul 7;101(1):19-26.
An algorithm for managing the failure of external beam radiotherapy in prostate cancer.
Dudderidge T, Payne H, Emberton M.
BJU Int. 2007 Sep;100(3):518-27. Epub 2007 Jun 15. Review.
Mitogenic growth signalling, DNA replication licensing, and survival are linked in prostate cancer.
Dudderidge TJ, et al
Br J Cancer. 2007 May 7;96(9):1384-93.
Mcm2, Geminin, and KI67 define proliferative state and are prognostic markers in renal cell carcinoma.
Dudderidge TJ, Stoeber K, Loddo M, Atkinson G, Fanshawe T, Griffiths DF, Williams GH.
Clin Cancer Res. 2005 Apr 1;11(7):2510-7.
Urinary markers in bladder cancer.
BJU Int. 2003 Nov;92(7):823-4. No abstract available.
Courses offered to GPs
Should I offer a PSA test? The modern diagnostic pathway for prostate cancer.
Community management of men after radical therapy for prostate cancer.
Diagnosis and management of scrotal disorders.
- FRCS Urology Royal College of Surgeons 2008
- MD University of Bristol 2014
- MBChB University of Bristol 1998
- MSc University College London 2003
Reference number 4505451
Details of entry to specialist register
- Urology, 2009
- Spire Southampton Hospital, SO16 6UY
- 13:30 - 18:00
- 023 8076 4391
Post treatment communication
Following treatment of a Bupa member, I will communicate with GPs in line with Department of Health, GMC and appropriate professional bodies guidelines.
In the event of an urgent query following treatment, Bupa members should use the following contact details
Spire Southampton Switchboard 023 8077 5544
(ask for the nurse in charge who will arrange admission and contact me)